Presentations from the Cresset User Group Meeting 2019
Thank you to all attendees who contributed to the success of the Cresset User Group Meeting 2019. As I'm sure ...
Virtual screening is being hailed by some as a superior method of evaluating compounds compared to high throughput screening. However, it’s still important to choose wisely between a ligand- or protein-based model template, as both are prone to mishandling.
In the June issue of Innovations in Pharmaceutical Technology, Cresset’s Tim Cheeseright and Rob Scoffin discuss virtual screening as a proven technology that can replace large-scale HTS runs in order to create a more focused data set for a smaller-scale screen.
Read the article in IPT, pages 16 to 19.